Fscan, Glide Pharma deal

FScan granted Glide exclusive, worldwide rights to technology to develop and commercialize a prostate cancer diagnostic. FScan will receive an undisclosed upfront payment and is eligible for undisclosed milestones and royalties. The non-invasive technology uses lanthanide complexes to measure citrate levels in seminal fluid. Glide also has the option to license other technologies for use in other indications. ...